Skip to main content
. Author manuscript; available in PMC: 2016 May 6.
Published in final edited form as: Curr Opin Genet Dev. 2015 Jan 20;30:17–24. doi: 10.1016/j.gde.2014.12.002

Figure 1. IDH1/2 mutations occurs early in gliomagenesis and is the fundamental prognostic marker.

Figure 1

The molecular classification systems that have been proposed are based on a number of different markers, the most fundamental of which may involve IDH1/2. IDH1/2-mutant and IDH1/2-wild type tumors follow two distinct genetic pathways with divergent clinical outcomes.